Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population‐based study
Transfusion2021Vol. 61(10), pp. 2877–2884
Citations Over TimeTop 23% of 2021 papers
Johanne Rozema, Eric N. van Roon, Robby E. Kibbelaar, Nic J.G.M. Veeger, Christiaan L. Slim, Harry de Wit, Mels Hoogendoorn
Abstract
This study provides a reliable estimate of the transfusion burden in real-world MDS patients, with almost half of the patients having a HTB. A HTB was observed in all MDS subtypes and both low- and high-risk MDS. Therefore, we conclude that the entire MDS population might benefit from novel agents that reduce the transfusion need and that might have beneficial effects on patient outcomes and healthcare utilization outcomes.
Related Papers
- → Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes(2012)170 cited
- → Infections in myelodysplastic syndromes(2012)116 cited
- → New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide(2015)8 cited
- → Erythroleukemia and Myelodysplastic Syndromes: An Historical Appraisal and aPersonalView(1993)9 cited
- → Myelodysplastic Syndromes (MDS)(2018)